Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Medicine’s Jonathan Miller, team discovers earlier history to Horner syndrome than originally believed
- CWRU ranks highest among Ohio schools in regards to salaries of alumni with bachelor’s degrees
- Traffic alert: Bellflower Road to be closed between East Boulevard and Ford Drive this evening
- Baker-Nord Center to kick off fall series with talk on “A Tale of Two Plantations”
- Engineering doctoral candidates receive American Society for Testing and Materials International scholarships